First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Sales growth in local currencies of 5% mainly driven by
VictozaⓇ and SaxendaⓇ
-
Sales as reported – first quarter of 2018
changing
diabetes
Growth
Other
hormone biopharmaceuticals
(10%)
(28%)
Haemophilia 6%
%
(3%)
Obesity
9%
2%
+43%
81%
Slide 6
Growth break down – first quarter of 2018
Local currencies
Growth
Share of growth
Long-acting insulin¹
(3%)
(10%)
Premix insulin²
Fast-acting insulin³
Human insulin
1%
2%
0%
0%
3%
4%
Diabetes care
(6%)
GLP-14
19%
73%
Other diabetes care5
5%
4%
Total diabetes care
5%
73%
Obesity (SaxendaⓇ)
64%
23%
Diabetes care and obesity total
6%
96%
Haemophilia6
7%
12%
Growth disorders
0%
0%
Other biopharmaceuticals?
(23%)
(8%)
Biopharmaceuticals
1%
4%
Total
5%
100%
Sales of DKK 26.9 billion (5%)
1 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 2 Comprises RyzodegⓇ and NovoMix®
3 Comprises FiaspⓇ and NovoRapidⓇ; 4 Comprises OzempicⓇ and VictozaⓇ
5 Primarily Novo NormⓇ and needles; 6 Comprises NovoSeven®, NovoEight®
NovoThirteenⓇ and Refixia®; 7 Primarily Vagifem® and Activelle®View entire presentation